We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Could Identify Patients at Risk for Severe Scleroderma

By LabMedica International staff writers
Posted on 16 Apr 2025

Systemic sclerosis, also known as scleroderma, causes the hardening of the skin and connective tissues. More...

In many cases, the disease can also damage vital organs, including the heart, kidneys, lungs, and gastrointestinal system, potentially leading to life-threatening complications. Among individuals diagnosed with systemic sclerosis, those with diffuse cutaneous systemic sclerosis generally experience a worse prognosis and higher mortality rate compared to those with limited cutaneous systemic sclerosis. Early diagnosis and intervention are crucial to slowing the progression of the disease, but currently, there are no clinical biomarkers to identify patients at higher risk for severe outcomes. Typically, doctors classify patients with suspected systemic sclerosis based on their symptoms: those with skin fibrosis limited to below the elbows and knees are diagnosed with limited cutaneous scleroderma, often experiencing less severe outcomes. On the other hand, patients with diffuse cutaneous systemic sclerosis, where skin fibrosis extends above the knees and elbows and affects other areas of the body, face a more aggressive disease course. Some of these patients may become disabled or develop progressive, debilitating conditions. A new test could now assist in identifying patients at risk for severe scleroderma, as highlighted in a study published in The Lancet Rheumatology.

In this groundbreaking study, researchers led by Yale School of Medicine (YSM, New Haven, CT, USA) demonstrated that type 1 interferons (IFNs)—a group of proteins that play a role in cell signaling—can serve as a blood biomarker for individuals with diffuse cutaneous systemic sclerosis. This discovery marks a significant advancement in early detection of high-risk patients. To find a reliable marker that could help clinicians predict poor outcomes in patients with diffuse cutaneous scleroderma, a team of clinician scientists from 11 academic centers across the United States collaborated to recruit patients with early-stage diffuse cutaneous systemic sclerosis. In 2012, they established the U.S. Prospective Registry of Early Systemic Sclerosis (PRESS), which includes patients who meet specific criteria for early diffuse cutaneous systemic sclerosis. The study involved 110 patients from the PRESS cohort. Simultaneously, researchers in the U.K. recruited a separate cohort of 32 healthy individuals and 72 patients with diffuse cutaneous systemic sclerosis as part of the Stratification for Risk of Progression in Scleroderma (STRIKE) study.

High levels of type 1 IFNs have been associated with worse outcomes in autoimmune diseases such as rheumatoid arthritis and lupus, but measuring blood serum levels of these IFNs is challenging. To address this, the researchers analyzed the concentrations of various molecules that respond to type 1 IFNs and are present in sufficient quantities for measurement, using them as indirect indicators of IFN activity. They discovered that participants in the PRESS cohort with high serum IFN scores tended to experience worse lung function and increased disability, including chronic joint pain, both at the start of the study and during follow-up. In the STRIKE cohort, patients with high IFN serum scores also exhibited poorer lung function, and these differences persisted throughout the study. Across both cohorts, individuals with elevated IFN scores had higher mortality rates than those with lower scores. As scleroderma-related lung disease is the leading cause of death in this patient population, identifying a blood biomarker that could predict patients at greater risk for lung disease is an important breakthrough. The researchers believe that the high serum IFN score could eventually be used to predict which patients, especially in the early stages of their disease, are at risk for developing severe conditions, facilitating more personalized and effective treatment strategies.

“Our results suggest that measuring type I IFN activity is akin to assessing the fuel driving autoimmune processes in systemic sclerosis patients,” said Monique Hinchcliff, MD, MS, at YSM. While additional validation and testing are necessary, “the ability to possibly discriminate between high-risk and low-risk patients with diffuse cutaneous systemic sclerosis using a blood test represents a large step forward for the community.”


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
STI Test
RIDA GENE STI Mycoplasma Panel
New
HbA1c Test
HbA1c Rapid Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.